Partnerships & Licensing
We identified DX-88 (ecallantide) and other compounds in our pipeline using our patented phage display technology.
Dyax also leverages this technology broadly with over 70 revenue-generating licenses and collaborations for therapeutic discovery, as well as in non-core areas such as affinity separations, diagnostic imaging, and research reagents.
Accessing Dyax's Phage Display Technology
Dyax offers licensing options to partners under the Licensing and Funded Research Program (LFRP). We also offer co-development and in-licensing opportunities.
Partners can benefit from the application of the same proprietary phage display technology, automation, and expertise that we apply to our own internal programs.
The LFRP has had tremendous success and has delivered high value to both our investors and our collaborators. The success of the LFRP is reflected by the clinical development of licensees' drug candidates. (see licensee pipeline)
- One approved product
- 16 product candidates in clinical trials
- Many preclinical programs
Agreements can be structured in a variety of ways and include:
- Funded research to discover and develop biotherapeutics on behalf of others
- Library licensing to allow a company to discover and develop biotherapeutics internally
- Licensing of phage display intellectual property
- Co-development
- In-licensing of novel targets from companies and academic institutions
(These libraries may also be licensed in areas outside Dyax's strategic focus, such as in vitro and in vivo diagnostics, research reagents, and the affinity purification of pharmaceuticals.)
Learn More
For more information about partnership and licensing opportunities, please contact our Business Development team.
